Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Ovarian Cancer
Anlotinib in Combination with TQB2450 in Patients with Recurrent Ovarian Cancer (ACTION)
Read More
Niraparib Efficacy and Safety in Patients with BRCA-Mutated Ovarian Cancer from 3 Phase 3 Trials
Read More
Real-World Treatment Patterns of Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer
Read More
Impact of the COVID-19 Pandemic on Ovarian Cancer Management: Adjusting to the New Normal
Read More
Immunologic Response to COVID-19 Vaccination in Patients with Ovarian Cancer Receiving PARP Inhibitors
Read More
Intervention of a Health Education Clinical Nursing Pathway Among Patients with Ovarian Carcinoma
Read More
Implementation of a Collaborative Model Provides Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer
Read More
Assessing Comprehensive Care Deficits in US Ovarian Cancer Programs to Inform Quality Improvement Initiatives
Read More
2021 in Review
Read More
Cost-Effectiveness Analysis of Olaparib and Niraparib as Maintenance Therapy for Women with Recurrent Platinum-Sensitive Ovarian Cancer
Read More
1
2
3
4
5
Page 2 of 13
Results 11 - 20 of 125
